PMID: 21108631

Cuthbert AW
New horizons in the treatment of cystic fibrosis.
Br J Pharmacol. 2011 May;163(1):173-83. doi: 10.1111/j.1476-5381.2010.01137.x., [PubMed]
Sentences
No. Mutations Sentence Comment
164 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:164:94
status: NEW
view ABCC7 p.Gly551Asp details
Class 3 mutations produce CFTR in which the regulation of the ion channel is disturbed, as in G551D, a relatively common mutation accounting for 3% of CF mutations. Login to comment
165 ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 21108631:165:212
status: NEW
view ABCC7 p.Arg117His details
Class 4 mutations allow the CFTR protein to be correctly translocated to the cell membrane but with reduced ion fluxes and altered selectivity because of mutations affecting the pore region of the channel, as in R117H. Login to comment
181 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:181:87
status: NEW
view ABCC7 p.Gly551Asp details
Epithelial cells (usually Fischer rat thyroid cells) expressing DF508 CFTR (or CFTR or G551D CFTR) together with the yellow fluorescent protein YP-H148Q that fluoresces in the presence of Cl- ions but not with I- ions, are grown on 100-well plates. Login to comment
193 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:193:127
status: NEW
view ABCC7 p.Gly551Asp details
Screening of a small library of benzoquinolizinium compounds showed that some of these not only activated CFTR, DF508 CFTR and G551D but also redirected the mutant forms to the correct cell location; that is, they were both correctors and potentiators (Becq et al., 1999; Dormer et al., 2001). Login to comment
211 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:211:139
status: NEW
view ABCC7 p.Gly551Asp details
For example, many of the antihypertensive 1,4 dihydropyridines, like nifedipine, nicardipine and nimodipine activated CFTR, DF508 CFTR and G551D (Pedemonte et al., 2005a). Login to comment
225 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:225:86
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 21108631:225:96
status: NEW
view ABCC7 p.Arg117His details
VX-770 was chosen on its ability to potentiate several forms of CFTR, including CFTR, G551D and R117H. Login to comment
228 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:228:34
status: NEW
view ABCC7 p.Gly551Asp details
In HBE cultures carrying both the G551D and the DF508 mutations VX-770 increased chloride secretion by ~10-fold, to ~50% of that observed in wild-type HBE epithelia. Login to comment
230 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:230:60
status: NEW
view ABCC7 p.Gly551Asp details
The initial clinical trial with VX770 was for patients with G551D mutations (~3% of the CF population) as the mutant protein is delivered to the membrane but cannot be activated. Login to comment
231 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21108631:231:74
status: NEW
view ABCC7 p.Gly551Asp details
Patch clamping studies showed that when expressed in FRT cells, the Po of G551D was increased from 0.1 to 0.45 by VX-770, while with DF508 CFTR, Po increased from 0.08 to 0.52 (Van Goor et al., 2009). Login to comment
251 ABCC7 p.Arg258Gly
X
ABCC7 p.Arg258Gly 21108631:251:46
status: NEW
view ABCC7 p.Arg258Gly details
ABCC7 p.Ser945Leu
X
ABCC7 p.Ser945Leu 21108631:251:53
status: NEW
view ABCC7 p.Ser945Leu details
ABCC7 p.His949Tyr
X
ABCC7 p.His949Tyr 21108631:251:63
status: NEW
view ABCC7 p.His949Tyr details
In one of these, VRT-325 rescued CFTR mutants R258G, S945L and H949Y as well as DF508 CFTR (Loo et al., 2005). Login to comment